Extending these findings to sensitivity to cancer therapies, TRPA1 was found to promote resistance to the traditional, platinum-based chemotherapeutic carboplatin through a mechanism dependent on the Ca2+-dependent anti-apoptotic mechanism. Here, TRPA1 is linked to cancer.